- Home
- BKU vs GKOS Comparison
BKU vs GKOS Comparison
Compare BKU & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKU
- GKOS
- Stock Information
- Founded
- BKU 2009
- GKOS 1998
- Country
- BKU United States
- GKOS United States
- Employees
- BKU N/A
- GKOS N/A
- Industry
- BKU Savings Institutions
- GKOS Medical/Dental Instruments
- Sector
- BKU Finance
- GKOS Health Care
- Exchange
- BKU Nasdaq
- GKOS Nasdaq
- Market Cap
- BKU N/A
- GKOS 5.1B
- IPO Year
- BKU 2011
- GKOS 2015
- Fundamental
- Price
- BKU $31.37
- GKOS $90.26
- Analyst Decision
- BKU Hold
- GKOS Strong Buy
- Analyst Count
- BKU 11
- GKOS 13
- Target Price
- BKU $41.55
- GKOS $155.00
- AVG Volume (30 Days)
- BKU 950.1K
- GKOS 1.0M
- Earning Date
- BKU 04-28-2025
- GKOS 04-30-2025
- Dividend Yield
- BKU 3.95%
- GKOS N/A
- EPS Growth
- BKU 29.58
- GKOS N/A
- EPS
- BKU 3.08
- GKOS N/A
- Revenue
- BKU $958,349,000.00
- GKOS $383,481,000.00
- Revenue This Year
- BKU $16.14
- GKOS $27.84
- Revenue Next Year
- BKU $7.01
- GKOS $27.99
- P/E Ratio
- BKU $10.18
- GKOS N/A
- Revenue Growth
- BKU 9.77
- GKOS 21.85
- 52 Week Low
- BKU $25.14
- GKOS $77.91
- 52 Week High
- BKU $44.45
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- BKU 43.94
- GKOS 41.57
- Support Level
- BKU $28.49
- GKOS $86.16
- Resistance Level
- BKU $32.92
- GKOS $94.55
- Average True Range (ATR)
- BKU 1.71
- GKOS 6.54
- MACD
- BKU 0.06
- GKOS 1.11
- Stochastic Oscillator
- BKU 49.69
- GKOS 54.51
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.